Qinghui Lianuo Presents Promising Early Clinical Data of Allogeneic B7-H3-Targeted CAR-γδ T Therapy QH104 for Leptomeningeal Metastasis at ASCO 2025

2025 American Society of Clinical Oncology（ASCO 2025）The annual meeting was held in Chicago, USA, from May 30 to June 3 local time. Beijing Qinghui Lianuo Biotechnology Co., Ltd.(hereinafter referred to as "Qinghui Lianuo")Announce itsSubmitted Allogeneic Universal B7 H3 CAR-γδ T Cell Drug QH104 for the Treatment of Leptomeningeal Metastases in Solid Tumors（Leptomeningeal Metastasis, LM）The abstract of the early clinical study has been successfully selected for the ASCO 2025 Annual Meeting and will be presented in detail in a poster format. Specific information is as follows:

Leptomeningeal metastasis is a late-stage solid tumor(such as lung cancer, breast cancer, etc.)The severe complication occurs at a rate of approximately 1-10%. Patients often experience rapid onset of severe headache, nausea and vomiting, neurological dysfunction, and other symptoms due to a sharp increase in intracranial pressure. The prognosis is extremely poor, with a median survival time of only a few weeks to months. Currently, there are no effective therapies specifically approved for LM worldwide, representing a significant unmet clinical need.

QH104 is the world's first universal allogeneic CAR γδ T cell therapy targeting B7 H3. B7 H3 is a protein expressed in a variety of solid tumors.(Including lung cancer, breast cancer, brain tumors, etc.)And its metastases(Such as LM)Widely highly expressed pan-tumor antigen in China. Combined with the innate tumor-homing capability of γδ T cells.(Especially for the central nervous system)And the potential for allogeneic universal use, administered intrathecally(Directly injected into the cerebrospinal fluid)Precision Delivery: QH104 Provides an Innovative Solution to Break Through the Blood-Brain Barrier Limitation and Directly Target LM Lesions, Offering Hope to Fill the Treatment Gap for This Fatal Complication. Previously, this product has received FDA clinical trial approval for high-grade gliomas. As clinical research advances, QH104 is expected to demonstrate its therapeutic potential in more types of solid tumors.

ASCO stands for American Society of Clinical Oncology(American Society of Clinical Oncology)Founded in 1964, it is the world's leading professional academic organization in the field of oncology, aiming to prevent cancer and improve cancer services. The ASCO Annual Meeting is the largest and most influential academic event in the global oncology field, showcasing the most cutting-edge clinical oncology research achievements and treatment technologies internationally every year. The conference gathers oncologists, researchers, doctors, and industry experts from around the world to discuss the latest cancer research and treatment methods. The theme of this year’s ASCO Annual Meeting is "Knowledge Driven, Taking Action: Creating a Better Future Together."（Driving Knowledge to Action: Building a Better Future）」。

Editorial Responsibility | Yong

Proofread by Jiebolian

Reference Source:

1.https://mp.weixin.qq.com/s/og214adiOJA3xjzRy7t7RQ

Dian Dian "Share”、“Like"and"In View", give me a little recharge~"